| Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ... JAMA oncology 4 (2), 173-182, 2018 | 815 | 2018 |
| Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast CancerHRD predicts … ML Telli, KM Timms, J Reid, B Hennessy, GB Mills, KC Jensen, Z Szallasi, ... Clinical cancer research 22 (15), 3764-3773, 2016 | 740 | 2016 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... New England Journal of Medicine 372 (2), 134-141, 2015 | 729 | 2015 |
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study JF Liu, WT Barry, M Birrer, JM Lee, RJ Buckanovich, GF Fleming, ... The Lancet Oncology 15 (11), 1207-1214, 2014 | 592 | 2014 |
| Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ... Nature 529 (7586), 413-417, 2016 | 530 | 2016 |
| Significance analysis of functional categories in gene expression studies: a structured permutation approach WT Barry, AB Nobel, FA Wright Bioinformatics 21 (9), 1943-1949, 2005 | 442 | 2005 |
| Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus … LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ... Journal of Clinical Oncology 34 (6), 542, 2016 | 361 | 2016 |
| A pathway-based classification of human breast cancer ML Gatza, JE Lucas, WT Barry, JW Kim, Q Wang, M D. Crawford, ... Proceedings of the National Academy of Sciences 107 (15), 6994-6999, 2010 | 360 | 2010 |
| Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401 A Hurria, CT Cirrincione, HB Muss, AB Kornblith, W Barry, AS Artz, ... Journal of clinical oncology 29 (10), 1290, 2011 | 340 | 2011 |
| Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer SM Wong, RA Freedman, Y Sagara, F Aydogan, WT Barry, M Golshan Annals of surgery 265 (3), 581-589, 2017 | 281 | 2017 |
| Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ... Journal of Clinical Oncology 37 (22), 1868, 2019 | 244 | 2019 |
| Public knowledge of and attitudes toward genetics and genetic testing SB Haga, WT Barry, R Mills, GS Ginsburg, L Svetkey, J Sullivan, ... Genetic testing and molecular biomarkers 17 (4), 327-335, 2013 | 230 | 2013 |
| Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients SM Tolaney, Y Boucher, DG Duda, JD Martin, G Seano, M Ancukiewicz, ... Proceedings of the National Academy of Sciences 112 (46), 14325-14330, 2015 | 218 | 2015 |
| Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line … HS Rugo, WT Barry, A Moreno-Aspitia, AP Lyss, C Cirrincione, E Leung, ... Journal of Clinical Oncology 33 (21), 2361, 2015 | 207 | 2015 |
| Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ... The Lancet Oncology 20 (4), 570-580, 2019 | 179 | 2019 |
| Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade … UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ... Annals of Oncology 28 (3), 512-518, 2017 | 178 | 2017 |
| CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer X Wang, T Osada, Y Wang, L Yu, K Sakakura, A Katayama, JB McCarthy, ... Journal of the National Cancer Institute 102 (19), 1496-1512, 2010 | 176 | 2010 |
| Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study Y Sagara, MA Mallory, S Wong, F Aydogan, S DeSantis, WT Barry, ... JAMA surgery 150 (8), 739-745, 2015 | 174 | 2015 |
| Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer DG Stover, HA Parsons, G Ha, SS Freeman, WT Barry, H Guo, ... Journal of Clinical Oncology 36 (6), 543, 2018 | 171 | 2018 |
| Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies MR Graham, K Virtaneva, SF Porcella, WT Barry, BB Gowen, CR Johnson, ... The American journal of pathology 166 (2), 455-465, 2005 | 167 | 2005 |
Hao GuoDepartment of Biostatsitics and Computational Biology, Dana-Farber Cancer InstituteVerified email at dfci.harvard.edu
